People: Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

103.73USD
29 Aug 2014
Price Change (% chg)

$0.78 (+0.76%)
Prev Close
$102.95
Open
$103.10
Day's High
$103.76
Day's Low
$103.01
Volume
2,224,720
Avg. Vol
1,819,575
52-wk High
$106.74
52-wk Low
$85.50

Search Stocks

Stoffels, Paulus 

Brief Biography

Dr. Paulus Stoffels is Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group of Johnson & Johnson. He joined the Company in 2002 with the acquisition of Virco and Tibotec, where he was Chief Executive Officer of Virco and Chairman of Tibotec. In 2005, he was appointed Company Group Chairman, Global Virology where he led the development of PREZISTA® and INTELENCE®, products for the treatment of HIV. In 2006, he assumed the role of Company Group Chairman, Pharmaceuticals, with responsibility for worldwide research and development for the CNS and Internal Medicine Franchises. Dr. Stoffels was appointed Global Head, Research & Development, Pharmaceuticals, in 2009, and in 2011 became Worldwide Chairman, Pharmaceuticals Group, with responsibility for research and development, business development and global strategy and innovation. In October 2012, Dr. Stoffels was appointed Chief Scientific Officer and a Member of the Executive Committee.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
3,369,730 -- 1,871,800 7,822,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 53,168 1,408,270.00
Name Fiscal Year Total

Alex Gorsky

16,911,000

Dominic Caruso

8,233,320

Sandra Peterson

5,637,260

Paulus Stoffels

7,822,000

Michael Ullmann

4,363,340

Peter Fasolo

3,621,280
As Of 28 Dec 2013
Search Stocks